Bepridil
Appearance
Clinical data | |
---|---|
Trade names | Vascor |
AHFS/Drugs.com | Monograph |
MedlinePlus | a699051 |
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Bioavailability | Well absorbed |
Protein binding | 99% |
Metabolism | Hepatic, CYP3A4-mediated |
Elimination half-life | 42 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H34N2O |
Molar mass | 366.54 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Bepridil (trade name Vascor) is an amine calcium channel blocker once used to treat angina. It is no longer sold in the United States.
It is nonselective.[1]
It has been discussed as a possible option in the treatment of atrial fibrillation.[2]
It has been implicated in causing ventricular arrhythmia (torsades de pointes).
Ebola research
In June 2015 a research paper [3] was published finding bepridil to result in a 100% survival rate for mice exposed to ebola during an experiment searching for potential pharmaceutical ebola treatments; indicating its potential use in future ebola research and therapy.[4]
References
- ^ Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
- ^ Imai S, Saito F, Takase H, et al. (May 2008). "Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm". Circ. J. 72 (5): 709–15. doi:10.1253/circj.72.709. PMID 18441448.
- ^ "A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity".
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ "Zoloft as Ebola cure? Antidepressant is one of a number of promising drugs being looked at by scientists".
External links